Entering text into the input field will update the search result below

Verona Pharma launches second part of ensifentrine study in lung disease

  • Verona Pharma (NASDAQ:VRNA) jumps 10% premarket after initiating the second, multiple dose, part of a Phase 2 trial to evaluate the pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a type of progressive lung disease characterized by long-term breathing problems and poor airflow.
  • Results from the study (Part B) are expected in H1 2021.
  • Positive efficacy and safety data from Part A of the study in 40 patients were announced on March 31, 2020.
  • Details of Part B Crossover trial are as follows:
  • Patient Population: Approx. 30 patients who participated in Part A are planned to continue to Part B at two sites in UK.
  • Dose/Duration: Patients will be randomized to receive 3 dose levels (300 µg, 1000 µg, 3000 µg) of pMDI ensifentrine or placebo, twice-daily over one week.
  • Primary Endpoint: Improvement in lung function as measured by peak FEV1 with ensifentrine compared to placebo after 7 days of treatment.
  • “Data from the single dose part of this pMDI study are very encouraging and consistent with data from Phase 2 clinical trials with our nebulized and dry powder inhaler formulations of ensifentrine," said David Zaccardelli, Pharm. D., President and CEO.

Recommended For You

More Trending News

About VRNA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VRNA--
Verona Pharma plc SPON ADR EACH REP 8 ORD SHS
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.